Kavar Capital Partners Group LLC Takes Position in Illumina, Inc. $ILMN

Kavar Capital Partners Group LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,056 shares of the life sciences company’s stock, valued at approximately $500,000.

Several other hedge funds have also modified their holdings of the stock. JPMorgan Chase & Co. raised its holdings in shares of Illumina by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after acquiring an additional 124,246 shares during the period. Elo Mutual Pension Insurance Co acquired a new position in Illumina in the 3rd quarter worth approximately $2,319,000. Nordea Investment Management AB boosted its stake in Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares during the period. Capital World Investors grew its position in Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new stake in Illumina during the 3rd quarter valued at $1,827,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $161.93 on Friday. The firm has a market cap of $24.50 billion, a price-to-earnings ratio of 29.44, a P/E/G ratio of 3.03 and a beta of 1.50. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $177.22. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The business has a fifty day simple moving average of $145.20 and a 200 day simple moving average of $136.16.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the company posted $0.97 earnings per share. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Royal Bank Of Canada started coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price for the company. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Wall Street Zen lowered Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Finally, Citigroup increased their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $142.12.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $98,400.00. Following the completion of the sale, the insider directly owned 21,568 shares in the company, valued at $3,450,880. The trade was a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the transaction, the chief accounting officer owned 14,446 shares in the company, valued at approximately $2,311,360. This trade represents a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,154 shares of company stock worth $155,600,208 in the last quarter. Corporate insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.